Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
6.40
-0.56 (-8.05%)
After Hours: 7.25 +0.85 (13.28%)
May 5, 5:50PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.40 - 7.09
52 week 4.14 - 7.74
Open 6.91
Vol / Avg. 0.00/623,618.00
Mkt cap 432.45M
P/E     -
Div/yield     -
EPS -0.78
Shares 69.22M
Beta 1.40
Inst. own 72%
Jun 28, 2016
Spectrum Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 1:30PM EDT - Add to calendar
May 10, 2016
Spectrum Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - 1:40PM EDT - Add to calendar
May 5, 2016
Q1 2016 Spectrum Pharmaceuticals Inc Earnings Call
May 5, 2016
Q1 2016 Spectrum Pharmaceuticals Inc Earnings Release
Mar 9, 2016
Q4 2015 Spectrum Pharmaceuticals Inc Earnings Call
Mar 9, 2016
Q4 2015 Spectrum Pharmaceuticals Inc Earnings Release
Feb 24, 2016
Spectrum Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -8.25% -31.24%
Operating margin -5.89% -25.06%
EBITD margin - -1.05%
Return on average assets -3.83% -11.15%
Return on average equity -7.80% -21.74%
Employees 212 -
CDP Score - -

Address

11500 S Eastern Ave Ste 240
HENDERSON, NV 89052-5576
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Spectrum Pharmaceuticals, Inc. is a biotechnology Company. The Company is engaged in commercial and drug development operations with a focus on hematology and oncology. The Company is engaged in acquiring, developing and commercializing the pipeline of late-stage clinical and commercial drug compounds. The Company market five drugs for the treatment of cancer, which includes FUSILEV injection for patients with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; FOLOTYN injection for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); MARQIBO injection for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia, and BELEODAQ injection for patients with relapsed or refractory PTCL.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Joseph W. Turgeon President, Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 61
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 56
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 79
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters